The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In late July, shares of Curis and Summit Therapeutics surged following positive clinical trial results for oncology treatments. During the same period, Curium entered negotiations to acquire Lantheus Holdings in a deal initially valued at $7 billion. By August 3, Curium officially finalized an agreement to purchase the radiopharmaceutical company for a total value of up to $8 billion.